Valneva closes €84m reserved offering to fund Lyme vaccine push
Valneva SE has completed an €84 million reserved offering, securing immediate proceeds of €37 million and a further €47 million contingent on the exercise of warrants attached to the newly issued shares. The dual-listed company — trading on Nasdaq under VALN and on Euronext Paris as VLA — said settlement and delivery are expected on 5 May 2026.
Frazier Life Sciences led the offering and increased its position in the company; new investors joining the register include TCGX, Deep Track Capital, Cormorant Asset Management, Perceptive Advisors, Vivo Capital, and Samsara BioCapital, alongside existing shareholder Nantahala. Jefferies, TD Cowen, and Stifel acted as global coordinators and joint bookrunners.
Deal structure and warrant mechanics
The 15,893,817 new ordinary shares were priced at €2.33 per unit — representing a 1.6% discount to Valneva's three-day volume-weighted average price ahead of pricing — with one warrant attached to each share. Each warrant entitles the holder to subscribe to one additional share at €2.96, a 25% premium to the same reference price. When accounting for the theoretical warrant value (estimated at €0.30 using a Black-Scholes model at 37.5% volatility), the effective discount to the three-day VWAP is 14.4%, the maximum permitted under the company's most recent shareholder mandate.
The exercise window for the warrants runs until 30 days after FDA approval of Valneva's six-valent OspA-based Lyme disease vaccine candidate — LB6V, developed in partnership with Pfizer — or until 31 March 2028 at the latest, with a possible automatic extension to September 2028 if a regulatory submission is under substantive FDA review by 1 March 2028. The structure effectively links the additional fundraise to the vaccine's regulatory outcome, giving investors a contingent upside tied directly to the programme's FDA timeline.
Valneva intends to split proceeds equally between advancing its pipeline and supporting working capital. The company held €109.7 million in cash at the end of 2025 and said existing resources were sufficient for at least 12 months without the new funding.
Market context and restructuring backdrop
The financing arrives at a moment of consolidation for Valneva. In November 2025 the company announced a rationalisation of its French operations, and it disclosed alongside this offering that a further restructuring — including workforce reductions — is under way, aimed at trimming costs while protecting its commercial travel vaccine business and key pipeline programmes.
The Lyme disease vaccine landscape has narrowed considerably in recent years, leaving LB6V as the only candidate in advanced clinical development. That near-monopoly positioning, allied to Pfizer's commercial infrastructure as co-development partner, gives the programme unusual commercial visibility should it reach approval. The FDA has not yet acted on a BLA filing; the warrant expiry mechanics suggest Valneva and its investors expect a regulatory decision within the next two to three years.
For specialist healthcare funds taking part in the reserved offering, the warrant structure represents an asymmetric bet: if FDA approval arrives, the exercise price of €2.96 per additional share could represent a material discount to the market price at that point. Conversely, if approval is delayed beyond September 2028 or does not materialise, the warrants lapse unexercised and the company has already banked the initial €37 million.
The issuance of the new shares dilutes existing shareholders by approximately 9.1% on a non-diluted basis; full warrant exercise would add a further 8.4%. Board members and executive officers are subject to a 60-day lock-up; investors in the offering are not.